The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study.
Turk J Med Sci
; 52(5): 1551-1558, 2022 Oct.
Article
in En
| MEDLINE
| ID: mdl-36422490
ABSTRACT
BACKGROUND:
We aimed to evaluate the efficacy of fulvestrant and its affecting clinical factors, including the optimal sequencing of fulvestrant and chemotherapy in a real-life cohort.METHODS:
The data of 256 metastatic hormone-positive breast cancer patients treated with fulvestrant were evaluated. The association of clinical factors with survival was analyzed with Kaplan-Meier and Cox-regression analyses.RESULTS:
The median age of patients was 57 years. More than half of the patients used fulvestrant in later lines and after chemotherapy (75.8%). The median progression-free (PFS) and overall survival (OS) of all cohort were 6.05 ± 0.56 and 29.70 ± 1.61 months, respectively. Primary endocrine resistance (HR 1.989, 95% CI 1.430-2.766, <0.001), use of fulvestrant after chemotherapy (HR 1.849, 95% CI 1.182-2.891, p = 0.007) and visceral metastases (HR 1.587, 95% CI 1.128-2.233, p = 0.008) were associated with decreased OS in multivariate analyses. Sixteen patients were treated with trastuzumab and fulvestrant combination. The overall response rate (p = 0.340), disease control rate (p = 0.076), and OS (p = 0.289) and PFS (p = 0.276) were similar to overall cohort.DISCUSSION:
In our experience, fulvestrant treatment was associated with comparable OS to clinical trials in a large cohort of patients. Patients treated with fulvestrant before chemotherapy were garnered significantly more benefit.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
Limits:
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Turk J Med Sci
Year:
2022
Document type:
Article
Affiliation country:
Turquía